AEON Biopharma, Inc. (AEON)vsRoyalty Pharma Plc (RPRX)
AEON
AEON Biopharma, Inc.
$0.28
+1.66%
HEALTHCARE · Cap: $13.03M
RPRX
Royalty Pharma Plc
$58.60
+0.47%
HEALTHCARE · Cap: $33.84B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 32.0% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 53/100 (C-).
AEON
Avoid17
out of 100
Grade: F
RPRX
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AEON.
Margin of Safety
-60.9%
Fair Value
$36.41
Current Price
$58.60
$22.19 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Generating 1.4B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 46.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AEON
The strongest argument for AEON centers on Debt/Equity.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth, Free Cash Flow. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : AEON
The primary concerns for AEON are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
AEON profiles as a value stock while RPRX is a growth play — different risk/reward profiles.
AEON carries more volatility with a beta of 0.64 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
RPRX generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (53/100 vs 17/100), backed by strong 32.0% margins and 16.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AEON Biopharma, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. The company is headquartered in Newport Beach, California.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?